Adicet Bio Inc Stock Price, News & Analysis

Adicet Bio (NASDAQ: ACET) reported its Q4 and full year 2024 financial results, highlighting progress in its gamma delta T cell therapy programs. The company maintains $176.3 million in cash position as of December 31, 2024, expected to fund operations into 2H 2026.

Key developments include:

• Ongoing Phase 1 trial of ADI-001 in autoimmune diseases, with preliminary lupus nephritis data expected in 1H25
• Patient enrollment expansion for ADI-001 in multiple conditions planned for 2Q25
• ADI-270 Phase 1 trial advancing in renal cell carcinoma patients
• Fast Track Designation received for ADI-001 in February 2025

Financial highlights: Q4 2024 net loss of $28.7 million ($0.32 per share), full-year 2024 net loss of $117.1 million ($1.33 per share). R&D expenses decreased to $99.3 million in 2024 from $106.0 million in 2023.

Adicet Bio (NASDAQ: ACET) announced two poster presentations for its ADI-270 therapy at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting in San Diego. The first presentation will showcase preclinical data comparing ADI-270, an armored allogeneic anti-CD70 γδ CAR T cell therapy, to conventional αβ CAR benchmarks in terms of efficacy and safety. The second presentation will detail a Phase 1/2 first-in-human study of ADI-270 in patients with relapsed or refractory clear cell renal cell carcinoma (ccRCC). The presentations are scheduled for March 12 and 13, 2025, respectively.

Adicet Bio (Nasdaq: ACET) has received FDA Fast Track Designation for its drug candidate ADI-001 targeting the treatment of adult patients with systemic sclerosis (SSc). The company, which specializes in developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, will benefit from an expedited review process designed for drugs addressing serious conditions with unmet medical needs.

Adicet Bio (NASDAQ: ACET) has received FDA Fast Track Designation for its drug candidate ADI-001, targeting the treatment of adult patients with refractory systemic lupus erythematosus (SLE) with extrarenal involvement. The designation is designed to expedite the development and review process for drugs addressing serious conditions with unmet medical needs.

The company, which specializes in developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, will benefit from accelerated development and review procedures for ADI-001.

Adicet Bio (NASDAQ: ACET) has announced inducement grants awarded on January 31, 2025. The company granted stock options to two new employees hired in January 2025, totaling 28,600 shares at an exercise price of $0.89 per share. Additionally, Dr. Julie Maltzman, the newly appointed Chief Medical Officer, received an inducement award of options to purchase 750,000 shares at the same exercise price.

The vesting schedule for all grants follows a four-year pattern: 25% vests after one year, with the remaining 75% vesting in 36 monthly installments, subject to continued employment. These awards were granted outside the company's stockholder-approved equity incentive plans through Adicet's 2022 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).

Adicet Bio (Nasdaq: ACET), a clinical stage biotechnology company focused on developing allogeneic gamma delta T cell therapies, has announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference. Chen Schor, the company's President and CEO, will engage in a fireside chat during the conference, which is scheduled for February 5-6, 2025, in New York.

The presentation is set for Wednesday, February 5, 2025, at 2:00 p.m. ET. Interested parties can access the live audio webcast through the Investors section of Adicet Bio's website. A replay of the presentation will remain available for 30 days following the event.

Adicet Bio (NASDAQ: ACET) provided updates on its clinical programs and 2025 milestones. The company is advancing a Phase 1 trial of ADI-001 across six autoimmune diseases, with preliminary data in lupus nephritis expected in 1H25 and other cohorts in 2H25. Patient enrollment for various conditions including systemic lupus erythematosus and systemic sclerosis is set to begin in Q1 2025.

The company has also dosed its first patient in the Phase 1 trial of ADI-270 for renal cell carcinoma, marking the first gamma delta CAR T cell therapy in clinical development for solid tumors. Preliminary data is expected in 1H25. Both ADI-001 and ADI-270 have received FDA Fast Track Designation for their respective indications.

Clinical biomarker data from the Phase 1 GLEAN trial demonstrated ADI-001's robust tissue trafficking and complete CD19+ B cell depletion in secondary lymphoid tissue, supporting its potential as an off-the-shelf treatment option.

Adicet Bio (Nasdaq: ACET) announced an inducement grant awarded on December 31, 2024. The company granted one new employee non-qualified stock options to purchase 9,000 shares of common stock at an exercise price of $0.96 per share. The vesting schedule includes 25% after one year, with the remaining 75% vesting monthly over three years, completing full vesting on the fourth anniversary. The grant was made under Adicet's 2022 Inducement Plan, approved outside the stockholder-approved equity incentive plans, and authorized by the compensation committee as a material inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Adicet Bio (Nasdaq: ACET), a clinical stage biotechnology company, has dosed the first patient in its Phase 1 clinical trial of ADI-270 for metastatic/advanced clear cell renal cell carcinoma (ccRCC), marking a significant milestone. ADI-270, an allogeneic gamma delta T cell therapy, aims to address the high unmet need for effective treatments in ccRCC, the most common type of kidney cancer. Preclinical data suggest ADI-270 has significant tumor infiltration capabilities, resistance to the immunosuppressive tumor microenvironment, and potent activity via CAR and innate-mediated targeting. Preliminary clinical data from the trial are expected in the first half of 2025.